Downregulation of RUNX2 significantly inhibited the growth of BLCA cells, promoted their apoptosis, and weaken their migration and invasiveness, suggesting that RUNX2 may be a prognostic biomarker and therapeutic target for BLCA. This evidence concerns the gene RUNX2 and bladder transitional cell carcinoma.